What is the significance of the FDA's approval of enlicitide decanoate?

The FDA's approval of Merck & Co.’s enlicitide decanoate marks the first approval of an oral (pill-based) PCSK9 inhibitor for reducing LDL-C in adults with hypercholesterolemia; it is marketed as Lipfendra and represents a novel therapeutic approach leveraging macrocyclic peptides—small, looped amino acid chains that combine the specificity of biologics with the bioavailability of small-molecule drugs.

How does enlicitide decanoate differ from existing PCSK9 inhibitors?

Unlike previously approved PCSK9 inhibitors—which are injectable monoclonal antibodies or siRNA therapies—enlicitide decanoate is the first orally administered PCSK9 inhibitor, enabled by its macrocyclic peptide structure that confers both target specificity and sufficient oral bioavailability.

FDA approves first oral PCSK9 inhibitor for managing cholesterol

Jul 16, 2026

The FDA approved Merck’s Lipfendra, the first oral PCSK9 inhibitor for reducing LDL cholesterol. Analysts project annual sales exceeding $2 billion, marking a significant milestone for macrocyclic peptide therapeutics.

cen

2026-07-16

FDA approves first oral PCSK9 inhibitor for managing cholesterol

FDA approves first oral PCSK9 inhibitor for managing cholesterol

FAQ